Introduction {#sec1}
============

Nitric oxide synthases (NOSs) are responsible for the biological production of nitric oxide (NO), an important second messenger that regulates many biological processes such as neurotransmission, vasodilation, and immune response.^[@ref1]^ NOSs catalyze two sequential reactions that convert [l]{.smallcaps}-arginine to [l]{.smallcaps}-citrulline and the free radical NO in the presence of oxygen and reduced nicotinamide adenine dinucleotide phosphate (NADPH) with *N*^ω^-hydroxy-[l]{.smallcaps}-arginine (NHA) as an intermediate.^[@ref2]−[@ref4]^

There are three mammalian NOS isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). All three isoforms are homodimers and share catalytic properties. However, according to various tissue distributions, NO generated from different NOS isoforms can play a wide range of physiological functions.^[@ref5],[@ref6]^ Overproduction of NO by nNOS has been implicated in many chronic neurodegenerative pathologies. Our previous studies have shown that NO from nNOS plays an important role in increasing the invasion and proliferation of human melanoma cells, suggesting that targeting NO signaling may facilitate therapy and prevention.^[@ref7]^ Although inhibition of nNOS activity is a promising strategy for the treatment of such diseases, inhibition of iNOS and eNOS, especially the latter, may cause undesired side effects.^[@ref8],[@ref9]^ Therefore, to precisely control biological processes and improve the safety profile, selective inhibition of nNOS over the other two isoforms is important for any potential therapeutic agent. The close similarity of active site structures in all three isoforms^[@ref10],[@ref11]^ presents a critical barrier to the design of selective nNOS inhibitors.

In our continuous efforts to develop nNOS selective inhibitors, we discovered a series of highly potent and selective nNOS small molecule inhibitors with a 2-aminopyridinomethyl pyrrolidine scaffold (Figure [1](#fig1){ref-type="fig"}, **1** and **2**).^[@ref12]−[@ref16]^ Some showed excellent potency (*K*~i~ \< 10 nM) and excellent selectivity for nNOS over eNOS (\>2500-fold) and iNOS (\>700-fold). Moreover, we have found that the 2-aminopyridine moiety not only can make hydrogen bonds (H-bonds) with the active site glutamate (Glu592 in nNOS or Glu363 in eNOS) but also can hydrogen bond with the heme propionate in a conformation flipped 180°, depending on the chirality of the pyrrolidine. To achieve the two possible enzyme--inhibitor H-bonding interactions with a single compound and to simplify the synthetic routes, we developed a series of symmetric double-headed aminopyridines (e.g., **3** in Figure [1](#fig1){ref-type="fig"}).^[@ref17],[@ref18]^ However, all of the aminopyridine-based inhibitors suffered from some limitations such as lack of oral bioavailability and/or poor membrane permeability. A fragment-based comparison of the in vitro enzyme assay versus the cellular assay clearly indicates that the aminopyridine moiety in these molecules may be an important factor that limits their membrane permeability.^[@ref19]^

![Chemical structures of **1**--**3**.](jm-2013-01252e_0002){#fig1}

In addition to the aminopyridine-based inhibitors, thiophene-2-carboximidamides (Figure [2](#fig2){ref-type="fig"}, **4**--**6**) represent another important class of nNOS inhibitors. Recently, some of these compounds were reported with promising pharmacological profiles.^[@ref20]−[@ref25]^ Despite their favorable pharmacokinetics, they have significant challenges to overcome with respect to their lower potency and isozyme selectivities in vitro compared with the aminopyridine-containing inhibitors. In addition, few crystal structures depicting the binding mode of these molecules to the NOS isoforms have been reported; therefore, more crystallographic studies of thiophene-2-carboximidamides would be highly desirable.

![Chemical structures of **4**--**6**.](jm-2013-01252e_0003){#fig2}

Both the 2-aminopyridine and thiophene-2-carboximidamide moieties exhibit similar H-bond interactions with the enzyme, acting as mimics of the guanidinium group of the natural substrate [l]{.smallcaps}-Arg. Taken together, the thiophene-2-carboximidamide fragment would serve as a bioisostere of the 2-aminopyridine fragment with the potential for improved pharmacological profiles. Here we adopted a hybrid strategy and designed and synthesized a series of compounds that combines the thiophene-2-carboximidamide fragment and structural features of our potent and selective double-headed aminopyridine inhibitors (Figure [3](#fig3){ref-type="fig"}). Furthermore, we conducted crystallographic studies to identify the inhibitor--enzyme interactions that promote nNOS-specific inhibition.

![Target molecules designed and synthesized in this study.](jm-2013-01252e_0004){#fig3}

Chemistry {#sec2}
=========

The synthesis of **7** began with 1-iodo-3-nitrobenzene (Scheme [1](#sch1){ref-type="scheme"}). Homocoupling of 1-iodo-3-nitrobenzene gave **18** in a moderate yield. The nitro groups of **18** were reduced to amino groups in a quantitative yield, and then coupling with methyl thiophene-2-carbimidothioate hydroiodide salt was used to generate final product **7**. The coupling reaction of 3,3′-methylenedianiline with methyl thiophene-2-carbimidothioate hydroiodide salt gave final product **8**.

![Synthesis of **7** and **8**\
Reagents and conditions: (a) Pd~2~(dba)~3~, tri(*o*-tolyl)phosphine, DIEA, 100 °C, 8 h, 61%; (b) Raney Ni, hydrazine hydrate, room temp, 30 min, quantitative; (c) EtOH, room temp, 24 h, 54--58%.](jm-2013-01252e_0010){#sch1}

A synthetic route for target molecule **9** is shown in Scheme [2](#sch2){ref-type="scheme"}. Wittig reaction of 3-nitrobenzaldehyde with the corresponding phosphorus ylide of 1-(bromomethyl)-3-nitrobenzene allowed the isolation of the intermediate alkene in an 87% yield. Compound **23** was obtained by reduction of **21**, followed by treatment with methyl thiophene-2-carbimidothioate hydroiodide salt. Catalytic hydrogenation of **23** reduced the double bond, giving final product **9** in a high yield.

![Synthesis of **9**\
Reagents and conditions: (a) PPh~3~, toluene, 90 °C, 12 h, 97%; (b) LHMDS, THF, −78 °C to room temp, 4 h, 87%; (c) Raney Ni, hydrazine hydrate, room temp, 30 min, quantitative; (d) EtOH, room temp, 24 h, 46%; (e) H~2~, Pd/C, EtOH, room temp, 24 h, 91%.](jm-2013-01252e_0011){#sch2}

Nucleophilic addition of 3-nitrophenol with 2-bromo-1-(3-nitrophenyl)ethanone yielded **24** (Scheme [3](#sch3){ref-type="scheme"}). The carbonyl group of **24** was reduced to a hydroxyl group. Reduction of **25** gave **26**, which was allowed to react with methyl thiophene-2-carbimidothioate hydroiodide salt to give **10**.

![Synthesis of **10**\
Reagents and conditions: (a) K~2~CO~3~, DMF, room temp, 6 h, 73%; (b) NaBH~4~, THF, room temp, 8 h, 80%; (c) Raney Ni, hydrazine hydrate, room temp, 30 min, quantitative; (d) EtOH, room temp, 24 h, 41%.](jm-2013-01252e_0012){#sch3}

Inhibitors **11** and **12** were synthesized as illustrated in Scheme [4](#sch4){ref-type="scheme"}. Nucleophilic addition of 3-nitrophenol with the corresponding alkyl halides generated **27** and **28**. Their nitro groups were reduced to give intermediates **29** and **30**, which were subsequently coupled with methyl thiophene-2-carbimidothioate hydroiodide salt to give final products **11** and **12**, respectively.

![Synthesis of **11** and **12**\
Reagents and conditions: (a) K~2~CO~3~, DMF, 60 °C, 6 h, 71--80%; (b) Raney Ni, hydrazine hydrate, room temp, 30 min, quantitative; (c) EtOH, room temp, 24 h, 59--58%.](jm-2013-01252e_0013){#sch4}

To synthesize inhibitors **13**--**17** (Scheme [5](#sch5){ref-type="scheme"}), reductive amination of 3-nitrobenzaldehyde with the corresponding amines generated **34**--**36**. The amino groups of **34**--**36** were protected with a Boc group. Reductive amination of **35** and **36** with acetaldehyde gave **40** and **41**, respectively. Amino group reduction and coupling with methyl thiophene-2-carbimidothioate hydroiodide salt were performed under conditions similar to those we adopted for the synthesis of **7**, giving target molecules **15**, **17**, and intermediates **47**--**49**. Deprotection of the Boc groups of **47**--**49** generated final products **13**, **14**, and **16**.

![Synthesis of **13**--**17**\
Reagents and conditions: (a) Et~3~N, NaBH~3~CN, THF, room temp, 12 h, 69--72%; (b) (Boc)~2~O, DMAP, MeOH, room temp, 12 h, 92--94%; (c) NaBH~3~CN, THF, room temp, 12 h, 58--64%; (d) Raney Ni, hydrazine hydrate, room temp, 30 min, quantitative; (e) EtOH, room temp, 24 h, 48--53%; (f) 3N HCl/MeOH, room temp, 24 h, quantitative.](jm-2013-01252e_0014){#sch5}

Results and Discussion {#sec3}
======================

Compounds **7**--**12** were designed with double thiophene-2-carboximidamide heads having diverse linkers. These flexible linkers mainly vary in length and, therefore, can provide precursor structural features that fit the enzyme active site appropriately. Table [1](#tbl1){ref-type="other"} shows the results of inhibition assays using purified NOS enzymes with **7**--**12**.

###### Inhibition of NOS Isozymes by Synthetic Inhibitors **7**--**12**[a](#t1fn1){ref-type="table-fn"}

           *K*~i~ (μM)     selectivity                        
  -------- --------------- ------------- -------------- ----- -----
  **7**    0.787 ± 0.061   66.4 ± 5.2    177.3 ± 10.9   84    225
  **8**    0.776 ± 0.069   79.0 ± 4.0    133.0 ± 12.4   102   171
  **9**    0.739 ± 0.053   103.8 ± 8.7   66.0 ± 5.8     141   89
  **10**   0.819 ± 0.067   10.1 ± 0.9    5.2 ± 0.4      12    6
  **11**   0.130 ± 0.062   66.8 ± 2.7    13.7 ± 0.7     513   105
  **12**   0.237 ± 0.019   12.6 ± 0.8    4.0 ± 0.3      53    17

The compounds were evaluated for in vitro inhibition against three NOS isozymes: rat nNOS, bovine eNOS, and murine iNOS. Considering that three NOS isozymes are isolated from three different species, the activity or selectivity of these compounds may differ in human NOS isozymes.^[@ref39]^

For this series, **7**--**10** display moderate inhibitory activity, while **11** and **12** are the best nNOS inhibitors. Compound **11** also shows outstanding nNOS selectivity over iNOS and good selectivity over eNOS. Compared to **11**, addition of one methylene group leads to a compound (**12**), with half the potency and a sharp decrease in selectivity for nNOS over both eNOS and iNOS.

To gain more insight into the structural basis for relative potencies and selectivities, we determined the crystal structure of several inhibitors bound to nNOS. The crystal structures revealed that **7** and **9** bind to nNOS as designed with one thiophene-2-carboximidamide head interacting with Glu592, while the other head occupies a hydrophobic pocket surrounded by Met336, Leu337, and Tyr706 near the active site entrance (Figure [4](#fig4){ref-type="fig"}). The two phenyl rings in **7** are in van der Waals contacts with both heme propionates (Figure [4](#fig4){ref-type="fig"}A). In contrast, having a 2-carbon linker between the two phenyl rings in **9** pushes the second phenyl and thiophene-2-carboximidamide head farther away from the heme (Figure [4](#fig4){ref-type="fig"}B). The Leu337 side chain must adopt an alternate rotamer to accommodate lengthy compound **9**. The second carboximidamide in **9** does not make any direct contacts with the protein, while that in **7** makes only a weak H-bond with heme propionate D. Therefore, the submicromolar binding affinity is mainly attributed to the first phenyl ring and the thiophene-2-carboximidamide head that tightly anchors the inhibitor to the NOS active site. The structure of **10** bound to nNOS (data not shown) also supports this conclusion. While the first phenyl ring and thiophene-2-carboximidamide head is clearly shown in the electron density, the remainder of the compound is disordered. Nevertheless, **10** shares a similar affinity to nNOS as **7** and **9** (Table [1](#tbl1){ref-type="other"}).

![Crystallographic binding conformation of **7** (A) and **9** (B) in rat nNOS. The omit *F*~o~ -- *F*~c~ electron density maps for the inhibitors are shown at the 2.5 σ contour level. Relevant H-bonds are depicted with dashed lines. Key distances are labeled in Å. All structural figures were prepared with PyMol ([www.pymol.org](www.pymol.org)).](jm-2013-01252e_0005){#fig4}

Compounds with a longer (4- or 5-atom) linker between the two head groups, **11** and **12**, exhibit much improved potency (Table [1](#tbl1){ref-type="other"}). The **11**-nNOS structure (Figure [5](#fig5){ref-type="fig"}A) provides an explanation. Similar to the cases of **7** and **9**, one phenyl ring and the thiophene-2-carboximidamide head of **11** recognizes the nNOS active site and H-bonds to Glu592 with the carboximidamide nitrogens. The O atom in the central linker distal to the active site forms a weak H-bond (3.4 Å) with Gln478. This brings the second phenyl ring next to Arg481. The Arg481 guanidinium plane has to rotate to make a better cation--aromatic stacking interaction with the phenyl ring of **11**. In addition, the N atom in the second head joins a H-bonding network involving Arg596, Asp600, and Arg603 via a water molecule. Interestingly, this thiophene-2-carboximidamide head reaches to a pocket surrounded by Trp306 (in the other subunit of the dimer), Asp600, Ser602, and Arg603 (Figure [5](#fig5){ref-type="fig"}B). This is the first time we have found an inhibitor reaching into this pocket. Sequence alignment reveals that Ser602 in nNOS is a His or a Gln at the corresponding positions in eNOS and iNOS, respectively. It is likely that interactions between the thiophene-2-carboximidamide and this unique hot spot affects the selectivity of **11** while the extensive aforementioned enzyme--inhibitor interactions account for the better potency. Linker length also is quite important because increasing the linker by one atom in going from **11** to **12** results in a 2-fold lower potency. The **12**-nNOS structure (data not shown) shows that while the first phenyl ring and thiophene-2-carboximidamide head clearly bind to the nNOS active site similarly to that of **11**, the other head is too flexible to be modeled with certainty.

![Crystallographic binding conformation of **11** with rat nNOS (A) and the new hot spot around the second thiophene head (B). The omit *F*~o~ -- *F*~c~ electron density maps for inhibitors are shown at the 2.5 σ contour level. Relevant H-bonds are depicted with dashed lines.](jm-2013-01252e_0006){#fig5}

nNOS has two negative charges in the active site (Glu592 and Asp597) compared to one in eNOS (Glu363). As a result, nNOS provides better electrostatic stabilization for positively charged inhibitors. Inspired by our previously reported highly selective and potent pyrrolidine-containing nNOS inhibitors (**1** and **2**), we introduced a basic nitrogen atom mimicking the pyrrolidine N atom in the linker part of **11**, leading to **13** and **14**, to enhance the binding affinity and selectivity (Table [2](#tbl2){ref-type="other"}). The results are impressive because both *K*~i~ values of **13** and **14** for nNOS are 5 nM, which is 25-fold more potent than that of **11**. Moreover, they display good selectivities of nNOS over iNOS and eNOS. The crystal structures of **13** and **14** bound to nNOS show that, as expected, both use the first phenyl ring and thiophene-2-carboximidamide head to anchor the inhibitor to the nNOS active site (Figure [6](#fig6){ref-type="fig"}). The newly introduced amino group in the linker is situated between the two heme propionates. These electrostatic interactions are very likely the main source of binding affinity gained by the two compounds. However, **13** and **14** have a different phenyl ring in the second head. While **13** bears a meta-bisubstituted phenyl ring, the one in **14** is para-bisubstituted. The structural differences around the phenyl ring influence the way the second thiophene-2-carboximidamide headgroup interacts with the protein. The head in **13** reaches the same pocket next to Ser602 described for **11** but through a different "route". This is because the new inhibitor--heme electrostatic interactions direct the second phenyl ring of **13** to pack against Met336 (Figure [6](#fig6){ref-type="fig"}A) rather than Arg481, as in the case of **11** (Figure [5](#fig5){ref-type="fig"}A). The second thiophene-2-carboximidamide head in **14** is partially disordered because the para-bisubstituted phenyl forces the thiophene tail toward the position of Trp306 (in the other subunit). The tail has to make a sharp turn to avoid clashes (Figure [6](#fig6){ref-type="fig"}B).

###### Inhibition of NOS Isozymes by Synthetic Inhibitors **13**--**15**[a](#t2fn1){ref-type="table-fn"}

           *K*~i~ (μM)      selectivity                      
  -------- ---------------- ------------- ------------ ----- -----
  **13**   0.005 ± 0.0005   1.3 ± 0.2     2.2 ± 0.1    260   440
  **14**   0.005 ± 0.0003   1.7 ± 0.1     2.7 ± 0.2    340   540
  **15**   0.049 ± 0.002    14.2 ± 0.8    41.4 ± 2.2   290   845

The compounds were evaluated for in vitro inhibition against three NOS isozymes: rat nNOS, bovine eNOS, and murine iNOS.

![Crystallographic binding conformation of **13** (A), **14** (B), and **15** (C) with rat nNOS. The omit *F*~o~ -- *F*~c~ electron density maps for inhibitors are shown at the 2.5 σ contour level. Relevant H-bonds are depicted with dashed lines. Key distances are drawn with dashed lines and labeled in Å.](jm-2013-01252e_0007){#fig6}

The basicity of the amine in the linker is important for potency, but this secondary amine is also a potential metabolic site that can be easily converted to a secondary hydroxylamine or serve as a substrate for flavin monooxygenases.^[@ref26]^ Therefore, we introduced a small ethyl group at the basic N atom of **14** to block this potential metabolic site. Such a substitution (**15**) decreases the potency (leading to an almost 10-fold drop in nNOS inhibition) but affords an increase in selectivity of nNOS over eNOS (845-fold). To our surprise, the **15**-nNOS structure reveals that **15** (Figure [6](#fig6){ref-type="fig"}C) binds to nNOS in an orientation 180° flipped from that of **14** (Figure [6](#fig6){ref-type="fig"}B). With **15**, it is the para-bisubstituted phenyl ring and its adjacent thiophene-2-carboximidamide that binds to Glu592. This orientation still allows a H-bond between the ethylated tertiary amine and heme propionate D. Inhibitor **14** is close to both heme propionates while **15** is close to only one, which may be the structural basis for why **14** is a more potent inhibitor. Nevertheless, the second phenyl ring and thiophene-2-carboximidamide head in **15** are quite well-defined, making van der Waals contacts with Met336, Leu337, and Trp306 (in the other subunit).

To understand isoform selectivity, we also determined the structures of **14**-eNOS and **15**-eNOS. As shown in Figure [7](#fig7){ref-type="fig"}A, **14** anchors its meta-bisubstituted phenyl ring and the connected thiophene-2-carboximidamide head to the eNOS active site next to Glu363, which is the same interaction seen in the **14**-nNOS structure. The salt bridges from the secondary amine in the linker of **14** to both heme propionates also exist in eNOS, which affords a low micromolar binding affinity of **14** to eNOS (Table [2](#tbl2){ref-type="other"}). However, the second phenyl and thiophene-2-carboximidamide head of **14** are less well-defined in eNOS. The residual electron density is nevertheless clear enough to indicate that the thiophene head steers away from the pocket where the same thiophene in **14**-nNOS establishes more favorable inhibitor--protein interactions. We hypothesize that the reason for this different binding preference stems from an amino acid variant, Ser602 in nNOS but His373 in eNOS. The bulkier His373 side chain in eNOS makes the pocket too shallow to accommodate the thiophene head of **14**.

![Crystallographic binding conformation of **14** (A) and **15** (B) with bovine eNOS. The omit *F*~o~ -- *F*~c~ electron density maps for inhibitors are shown at the 2.5 σ contour level. Relevant H-bonds are depicted with dashed lines. Key distances are drawn with dashed lines and labeled in Å.](jm-2013-01252e_0008){#fig7}

The inhibitor binding mode observed in the **15**-eNOS structure (Figure [7](#fig7){ref-type="fig"}B) is almost the same as that seen in the **15**-nNOS structure (Figure [6](#fig6){ref-type="fig"}C). That is, the para-bisubstituted phenyl ring brings the thiophene-2-carboximidamide next to Glu363 on one end and the tertiary amine next to heme propionate D on the other end, for H-bonds. This means that the 845-fold selectivity of **15** for nNOS over eNOS (Table [2](#tbl2){ref-type="other"}) is associated with how the tail end of the inhibitor extending out of the active site interacts with the protein. Unfortunately, the position of this thiophene ring is less certain because of poorer density in this region in both the **15**-eNOS and **15**-nNOS structures. Even so, there are sufficient sequence differences in this area to provide a possible explanation for selectivity. The main difference is that Met336 in nNOS is Val106 in eNOS. The second phenyl ring of **15** in eNOS makes van der Waals contacts with Val106 and Leu107, while the same group in nNOS contacts Met336 and Leu337. As a result, there is the potential for greater nonpolar interactions in nNOS. Another factor is the contacts between the thiophene ring and a Trp side chain (Trp306 in nNOS or Trp76 in eNOS). These contacts are closer in nNOS than those in eNOS.

Changing the secondary amine in **14** to a tertiary amino in **15** improves selectivity. To explore whether such substitution is effective in other cases, especially in mono-thiophene-2-carboximidamide nNOS inhibitors, we designed and synthesized **16** and **17** (Table [3](#tbl3){ref-type="other"}). One thiophene-2-carboximidamide head was replaced by a fluorobenzene fragment because fluorine has been widely used to alter the pharmacokinetic properties and overall drug-like properties of compounds.^[@ref27]^ Compound **16** drops about half of the nNOS inhibitory activity compared to parent compound **14**, and selectivity also decreases sharply, especially over eNOS. However, addition of an ethyl group at the basic nitrogen of **16** further enhances the nNOS over eNOS selectivity although it decreases the potency (Table [3](#tbl3){ref-type="other"}), which shows the same trend as **14** and **15**. The reason for decreased potency may be the shorter length, thereby preventing additional van der Waals contacts with the protein that are afforded by the longer thiophene-2-carboximidamide head in **14**. Detailed interactions of **16** and **17** are shown in Figure [8](#fig8){ref-type="fig"}.

###### Inhibition of NOS Isozymes by Synthetic Inhibitors **16** and **17**[a](#t3fn1){ref-type="table-fn"}

           *K*~i~ (μM)     selectivity                       
  -------- --------------- ------------- ------------- ----- -----
  **16**   0.011 ± 0.001   1.6 ± 0.07    0.9 ± 0.05    145   82
  **17**   0.073 ± 0.003   12.1 ± 0.74   21.7 ± 1.57   166   297

The compounds were evaluated for in vitro inhibition against three NOS isozymes: rat nNOS, bovine eNOS and murine iNOS.

![Crystallographic binding conformation of **16** (A) and **17** (B) with rat nNOS, as well as **16** (C) and **17** (D) with bovine eNOS. The omit *F*~o~ -- *F*~c~ electron density maps for inhibitors are shown at the 2.5 σ contour level. Relevant H-bonds are depicted with dashed lines. Key distances are drawn with dashed lines and labeled in Å.](jm-2013-01252e_0009){#fig8}

Indeed, the structure of **16**-nNOS (Figure [8](#fig8){ref-type="fig"}A) reveals that apart from the common features of NOS active site recognition through the thiophene-2-carboximidamide head seen for other analogues, the fluorobenzene head of **16** interacts only with Trp306 (other subunit). Compound **17** shows ∼7-fold lower potency than **16**, mainly because it maintains only one H-bond with heme propionate A via its tertiary amine (Figure [8](#fig8){ref-type="fig"}B), while the secondary amine in **16** makes H-bonds/salt bridges with both heme propionates (Figure [8](#fig8){ref-type="fig"}A). Moreover, the fluorobenzene in the **17**-nNOS complex has higher flexibility with weaker electron density, making a new hydrophobic interaction with Tyr706. This interaction forces the phenyl group of Tyr706 to rotate about 70° from what is seen in the **16**-nNOS structure. Although **17** is a weaker binder than **16**, the former has better selectivity (Table [3](#tbl3){ref-type="other"}). The crystal structure shows that **16** (Figure [8](#fig8){ref-type="fig"}C) binds to eNOS in an almost identical manner as that found in the **16**-nNOS structure (Figure [8](#fig8){ref-type="fig"}A), and **17** also binds to eNOS (Figure [8](#fig8){ref-type="fig"}D) similar to nNOS (Figure [8](#fig8){ref-type="fig"}B). The only difference for **16** is the orientation of the F atom from fluorobenzene. In eNOS the F atom points toward Val106 and Leu107 for van der Waals contacts. To avoid clashes with the fluorobenzene of **16** (or **17**), the Tyr477 side chain rotates, as we observed with **17**-nNOS (Figure [8](#fig8){ref-type="fig"}B). The subtle difference between **17**-eNOS (Figure [8](#fig8){ref-type="fig"}D) and **17**-nNOS (Figure [8](#fig8){ref-type="fig"}B) is also only in the position of fluorobenzene, which might be attributed to the amino acid variation in the vicinity. Met336 in nNOS is corresponds to Val106 in eNOS. Hydrophobic contacts (∼3.5--3.9 Å) found between the fluorobenzene and Val106/Leu107 in **17**-eNOS are closer than those contacts (∼4.3--4.8 Å) to Met336/Leu337 seen with **17**-nNOS. Although it is not clear that the differences near the tail end of the inhibitors is the explanation for isoform selectivity, it is clear that attaching an ethyl group to the secondary amine is a useful method to improve the nNOS/eNOS selectivity of these thiophene compounds.

Given the enzyme potency of **13** and **14**, we next tested whether these inhibitors were effective in melanoma cell lines. Detailed in our previous study,^[@ref7]^ nNOS is associated with the proliferation of melanoma and increased invasion, leading to subsequent development of metastases. nNOS inhibitors were able to efficiently inhibit melanoma proliferation and invasion with significant reduction of intracellular NO levels. Inhibitors **13** and **14** exhibited potent antimelanoma activity in vitro (Table [4](#tbl4){ref-type="other"}). Their EC~50~ values in metastic melanoma A375 cells are 1.3 and 3.4 μM (Table [4](#tbl4){ref-type="other"}), which is better than that of the chemotherapeutic drug cisplatin (4.2 and 14.3 μM in A375 and Sk-Mel28 cells, respectively).^[@ref7]^ Notably, the inhibition by **13** and **14** is more predominant in metastatic melanoma A375 cells compared to primary early stage Wm3211 cells, which supports our hypothesis that nNOS/NO signaling is more critical to melanoma progression than to the initiation phase. However, unexpectedly, these compounds also exhibited apparent inhibition of cell proliferation in primary normal cells, including melanocytes and fibroblast cells. Taken together, these results suggest that targeting nNOS provides a potential approach to block overactivated NO signaling in human melanoma.

###### EC~50~ Values (μM) of **13** and **14** with Human Melanoma Cells

  compd    primary melanoma wm3211 cell line   metastatic melanoma A375 cell line   primary fibroblast cells          primary keratinocytes                      immortalized melanocytes
  -------- ----------------------------------- ------------------------------------ -------------------------- ------------------------------------ --------------------------------------------------
  **13**   5.6                                 3.4                                  1.4                         ND[a](#t4fn1){ref-type="table-fn"}   cannot calculate[b](#t4fn2){ref-type="table-fn"}
  **14**   2.7                                 1.3                                  7.9                                  cannot calculate                            cannot calculate

Not done.

Toxic even at lower concentration and no dose--activity curve occurred.

Conclusions {#sec4}
===========

In summary, we report the rational design of selective nNOS inhibitors using a hybrid strategy. Two compounds, **13** and **14**, show excellent potency (5 nM) and good selectivities for nNOS over the other isozymes. The crystal structures of these inhibitors bound to nNOS or eNOS have identified a new hot spot near Ser602 in nNOS (Figure [5](#fig5){ref-type="fig"}B). The equivalent residue in eNOS is His373, which may be a contributing structural factor for the selectivity observed for **14** (Figure [6](#fig6){ref-type="fig"}). A small ethyl substituent attached to the amine of the inhibitor acts as an important component for improving isoform selectivity. Importantly, **13** and **14** achieve good cellular activity in two melanoma cell lines. Altogether, these inhibitors are promising candidates for further development of improved therapeutics, and their structural features provide new clues for the future design and development of new selective nNOS inhibitors.

Experimental Section {#sec5}
====================

All reagents were purchased from Sigma-Aldrich, Alfa Aesar, or TCI and were used without further purification unless stated otherwise. Analytical thin layer chromatography was visualized by ultraviolet light. Flash column chromatography was carried out under a positive pressure of air. ^1^H NMR spectra were recorded on 500 or 400 MHz spectrometers. Data are presented as follows: chemical shift (in ppm on the δ scale, and the reference resonance peaks set at 0 ppm \[TMS(CDCl~3~)\] and 3.31 ppm (CD~2~HOD), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = quintet, m = multiplet), coupling constant (*J*/Hz), and integration. ^13^C NMR spectra were recorded at 125 or 100 MHz, and all chemical shift values are reported in ppm on the δ scale, with an internal reference of δ 49.0 for CD~3~OD. High-resolution mass spectra were measured on liquid chromatography/time-of-flight mass spectrometry (LC-TOF). The purity of the tested compounds was determined by high-performance liquid chromatography (HPLC) analysis and was \>95%.

General Procedure A: Nitro Group Reduction {#sec5.1}
------------------------------------------

To a solution of the reagent (1 mmol) in MeOH (10.0 mL) was added hydrazine hydrate (0.2 mL) and Raney nickel. The reaction mixture was stirred at room temperature for 30 min. Then the reaction mixture was filtered through Celite. The filtration was diluted with water, extracted with EtOAc, and washed with saturated NaHCO~3~ and brine. The organic layer was concentrated in vacuo. The residue was purified by column chromatography to yield the product.

General Procedure B: Reductive Amination {#sec5.2}
----------------------------------------

To a solution of the aldehyde (1.0 mmol) and amine (1.0 mmol) in THF (20 mL) at 0 °C was added NaBH~3~CN (1.05 mmol) in three portions carefully. The reaction mixture was stirred at 0 °C for 30 min and then stirred overnight at room temperature. The reaction mixture was quenched with MeOH in an ice bath, extracted with EtOAc, and washed with saturated NaHCO~3~ and brine. The organic layer was concentrated in vacuo. The residue was purified by column chromatography to yield product.

General Procedure C: Boc-Protection {#sec5.3}
-----------------------------------

To a solution of the amine (1 mmol) in MeOH (15 mL) was added di-*tert*-butyl dicarbonate (1.2 equiv) and DMAP (cat.). The reaction mixture was stirred at room temperature for 12 h. Then the reaction mixture was concentrated in vacuo. The residue was purified by column chromatography to yield the product.

General Procedure D: Coupling Reaction of Amine with Methyl Thiophene-2-carbimidothioate Hydroiodide Salt {#sec5.4}
---------------------------------------------------------------------------------------------------------

To a solution of the amine (1 mmol) in EtOH (15.0 mL) was added thiophene-2-carbimidothioate hydroiodide salt (1.5 equiv for monoamine and 3.0 equiv for diamine). The reaction mixture was stirred at room temperature for 36 h. Then the reaction mixture was concentrated in vacuo. The residue was purified by column chromatography to yield product.

General Procedure E: Boc-Deprotection {#sec5.5}
-------------------------------------

To a solution of the Boc-protected reagent (0.2 mmol) in MeOH (1.0 mL) was added 3N HCl (10.0 mL). The reaction mixture was stirred at room temperature for 24 h. Then the reaction mixture was concentrated in vacuo. The crude product was recrystallized with MeOH and cold diethyl ether to provide the product.

*N*,*N*′-(\[1,1′-Biphenyl\]-3,3′-diyl)bis(thiophene-2-carboximidamide) (**7**) {#sec5.5.1}
------------------------------------------------------------------------------

To a solution of 1-iodo-3-nitrobenzene (3.0 mmol) in dry DIEA (20 mL) was added Pd~2~(dba)~3~ (0.05 equiv) and tri(*o*-tolyl)phosphine (0.1 equiv). The reaction mixture was stirred under argon at 100 °C for 8 h and then diluted with H~2~O, extracted with EtOAc, and washed with water and brine. The organic layer was dried over Na~2~SO~4~ and concentrated in vacuo. The residue was purified by column chromatography to yield **18** (yield 61%). **7** was synthesized by general procedures A and D using **18** as the starting material (yield 54%). ^1^H NMR (500 MHz, CD~3~OD): δ 7.68 (d, *J* = 3.5 Hz, 2H), 7.60 (d, *J* = 5.0 Hz, 2H), 7.46 (t, *J* = 7.5 Hz, 2H), 7.40 (d, *J* = 7.5 Hz, 2H), 7.26 (s, 2H), 7.15 (dd, *J* = 5.0, 3.5 Hz, 2H), 7.00 (d, *J* = 7.5 Hz, 2H). ^13^C NMR (125 MHz, CD~3~OD): δ 156.61, 140.59, 135.37, 134.96, 134.59, 130.65, 129.07, 128.62, 126.63, 125.25, 124.12. LC-TOF (M + H^+^) calcd for C~22~H~19~N~4~S~2~ 403.1046, found 403.1046.

*N*,*N*′-(Methylenebis(3,1-phenylene))bis(thiophene-2-carboximidamide) (**8**) {#sec5.5.2}
------------------------------------------------------------------------------

Compound **8** was synthesized by general procedure D using 3,3′-methylenediamiline as the starting material (yield 58%). ^1^H NMR (500 MHz, CD~3~OD): δ 8.10--8.00 (m, 4H), 7.53 (t, *J* = 7.5 Hz, 2H), 7.41--7.36 (m, 6H), 7.34 (d, *J* = 7.5 Hz, 2H), 4.18 (s, 2H). ^13^C NMR (125 MHz, CD~3~OD): δ 159.39, 144.70, 135.82, 135.50, 135.15, 131.76, 130.92, 130.30, 130.02, 127.25, 124.71, 41.99. LC-TOF (M + H^+^) calcd for C~23~H~21~N~4~S~2~ 417.1202, found 417.1195.

*N*,*N*′-(Ethane-1,2-diylbis(3,1-phenylene))bis(thiophene-2-carboximidamide) (**9**) {#sec5.5.3}
------------------------------------------------------------------------------------

LHMDS (1.0 M in THF, 2.4 mmol) was added to a suspension of **20** (2 mmol) in anhydrous THF (15 mL) at −78 °C. The reaction mixture was stirred under argon for 30 min, then warmed to 0 °C over 30 min. To this reaction mixture was added 3-nitrobenzaldehye (2.2 mmol) in anhydrous THF (3 mL) at −78 °C. The reaction mixture was warmed to room temperature and stirred for 4 h. The reaction mixture was then quenched with saturated NH~4~Cl, extracted with EtOAc, and washed with water and brine. The organic layer was concentrated in vacuo. The residue was purified by column chromatography to yield **21** (yield 87%). Intermediate **24** was synthesized by general procedures A and D using **21** as the starting material (yield 46%). A solution of **24** (0.5 mmol) in MeOH (20 mL) was treated with 10% Pd/C (15 mg). The reaction mixture was stirred at room temperature under a hydrogen atmosphere for 24 h. The catalyst was removed by filtration through Celite, and the resulting solution was concentrated in vacuo. The crude material was purified by column chromatography to yield **9** (yield 91%). ^1^H NMR (400 MHz, CD~3~OD): δ 8.17--8.02 (m, 4H), 7.56--7.51 (t, *J* = 7.5 Hz, 2H), 7.45--7.38 (m, 6H), 7.36--7.30 (d, *J* = 7.5 Hz, 2H), 3.10 (s, 4H). ^13^C NMR (100 MHz, CD~3~OD): δ 156.90, 143.97, 136.57, 133.15, 132.73, 130.64, 129.92, 128.32, 128.26, 125.00, 122.43, 36.92. LC-TOF (M + H^+^) calcd for C~24~H~23~N~4~S~2~ 431.1359, found 431.1359.

*N*-(3-(1-Hydroxy-2-(3-(thiophene-2-carboximidamido)phenoxy)ethyl)phenyl)thiophene-2-carboximidamide (**10**) {#sec5.5.4}
-------------------------------------------------------------------------------------------------------------

To a solution of 3-nitrophenol (2 mmol) in DMF (20 mL) was added K~2~CO~3~ (2.2 mmol) and 2-bromo-1-(3-nitrophenyl)ethanone (2.2 mmol). The suspension was stirred for 6 h at room temperature. The reaction mixture was then diluted with H~2~O (50 mL), extracted with EtOAc, and washed with water and brine. The organic layer was dried over Na~2~SO~4~ and concentrated in vacuo. The residue was purified by column chromatography to yield **24** (yield 73%). To a solution of **24** (1 mmol) in THF (10 mL) was added NaBH~4~ (1.2 mmol) in three portions. The reaction mixture was stirred at room temperature for 8 h under a N~2~ atmosphere. The reaction mixture was quenched with H~2~O (20 mL), extracted with CH~2~Cl~2~, and washed with water and brine. The organic layer was dried over Na~2~SO~4~ and concentrated in vacuo. The residue was purified by column chromatography to yield **25** (yield 80%). **10** was synthesized by general procedures A and D using **25** as the starting material (yield 41%). ^1^H NMR (500 MHz, CD~3~OD): δ 7.62 (dt, *J* = 7.5, 3.5 Hz, 2H), 7.58--7.51 (m, 2H), 7.37 (t, *J* = 7.5 Hz, 1H), 7.25 (t, *J* = 7.5 Hz, 1H), 7.20 (d, *J* = 7.5 Hz, 1H), 7.13--7.07 (m, 3H), 6.93 (dt, *J* = 7.5, 2.5 Hz, 1H), 6.69 (dd, *J* = 7.5, 2.5 Hz, 1H), 6.60--6.54 (m, 2H), 5.05--5.00 (m, 1H), 4.15--4.00 (m, 2H). ^13^C NMR (125 MHz, CD~3~OD): δ 161.37, 144.06, 131.34, 130.62, 129.88, 128.51, 128.38, 123.20, 122.77, 121.79, 116.23, 110.97, 110.09, 74.18, 73.46. LC-TOF (M + H^+^) calcd for C~24~H~23~N~4~O~2~S~2~ 463.1257, found 463.1256.

*N*,*N*′-((Ethane-1,2-diylbis(oxy))bis(3,1-phenylene))bis(thiophene-2-carboximidamide) (**11**) {#sec5.5.5}
-----------------------------------------------------------------------------------------------

To a solution of 3-nitrophenol (2 mmol) in DMF (20 mL) was added K~2~CO~3~ (2.2 mmol) and 1,3-dibromopropane (1 mmol). The suspension was then stirred for 6 h at 60 °C. The reaction mixture was then diluted with H~2~O (50 mL), extracted with EtOAc, and washed with water and brine. The organic layer was dried over Na~2~SO~4~ and concentrated in vacuo. The residue was purified by column chromatography to yield **27** (yield 80%). **11** was synthesized by general procedures A and D using **27** as the starting material (yield 59%). ^1^H NMR (500 MHz, CD~3~OD): δ 8.01 (t, *J* = 4.0 Hz, 4H), 7.47 (t, *J* = 8.0 Hz, 2H), 7.33 (t, *J* = 4.0 Hz, 2H), 7.03 (dd, *J* = 8.0, 2.0 Hz, 2H), 6.97 (t, *J* = 2.0 Hz, 2H), 6.94 (dd, *J* = 8.0, 2.0 Hz, 2H), 4.43 (s, 4H). ^13^C NMR (125 MHz, CD~3~OD): δ 161.52, 157.72, 133.75, 133.12, 132.15, 129.64, 129.49, 118.15, 114.83, 112.12, 68.12. LC-TOF (M + H^+^) calcd for C~24~H~23~N~4~O~2~S~2~ 463.1257, found 463.1257.

*N*,*N*′-((Propane-1,3-diylbis(oxy))bis(3,1-phenylene))bis(thiophene-2-carboximidamide) (**12**) {#sec5.5.6}
------------------------------------------------------------------------------------------------

**12** was synthesized by the same procedures as those to prepare **11** using 1,4-dibromobutane as the starting material. ^1^H NMR (500 MHz, CD~3~OD): δ 8.09--7.99 (m, 4H), 7.49 (t, *J* = 8.0 Hz, 2H), 7.41--7.33 (m, 2H), 7.11--7.05 (dd, *J* = 8.0, 2.5 Hz, 2H), 7.03 (t, *J* = 2.5 Hz, 2H), 7.00 (dd, *J* = 8.0, 2.5 Hz, 2H), 4.28 (t, *J* = 6.0 Hz, 4H), 2.33 (p, *J* = 6.0 Hz, 2H). ^13^C NMR (125 MHz, CD~3~OD): δ 161.77, 158.79, 146.61, 134.93, 134.51, 132.32, 129.83, 118.43, 115.89, 112.62, 65.88, 30.21. LC-TOF (M + H^+^) calcd for C~25~H~25~N~4~O~2~S~2~ 477.1413, found 477.1411.

*N*-(3-(2-((3-(Thiophene-2-carboximidamido)benzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide (**13**) {#sec5.5.7}
---------------------------------------------------------------------------------------------------------

**13** was synthesized by general procedures B, C, A, D, and E using 3-nitrobenzaldehyde and 2-(3-nitrophenyl)ethanamine as the starting materials. ^1^H NMR (500 MHz, CD~3~OD): δ 7.65 (t, *J* = 5.0 Hz, 2H), 7.56 (dt, *J* = 5.0, 2.0 Hz, 2H), 7.38--7.27 (m, 2H), 7.17--7.09 (m, 2H), 7.06 (dt, *J* = 7.5, 1.5 Hz, 1H), 7.01--6.94 (m, 2H), 6.91 (dt, *J* = 7.5, 1.5 Hz, 1H), 6.88--6.82 (m, 2H), 3.79 (s, 2H), 2.96--2.81 (m, 4H). ^13^C NMR (125 MHz, CD~3~OD): δ 161.52, 153.94, 150.23, 142.53, 141.90, 141.06, 130.73, 130.67, 129.87, 129.83, 128.49, 128.39, 125.03, 124.76, 123.95, 123.69, 122.60, 121.58, 54.30, 51.28, 36.59. LC-TOF (M + H^+^) calcd for C~25~H~26~N~5~S~2~ 460.1624, found 460.1618.

*N*-(4-(2-((3-(Thiophene-2-carboximidamido)benzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide (**14**) {#sec5.5.8}
---------------------------------------------------------------------------------------------------------

**14** was synthesized by the same procedures as those to prepare **13** using 2-(4-nitrophenyl)ethanamine as the starting material. ^1^H NMR (500 MHz, CD~3~OD): δ 7.65--7.58 (m, 2H), 7.58--7.51 (m, 2H), 7.33 (t, *J* = 7.5 Hz, 1H), 7.24--7.17 (m, 2H), 7.13--7.07 (m, 2H), 7.04 (dt, *J* = 7.5, 2.0 Hz, 1H), 6.95 (t, *J* = 2.0 Hz, 1H), 6.93--6.85 (m, 3H), 3.84--3.70 (m, 2H), 2.93--2.74 (m, 4H). ^13^C NMR (125 MHz, CD~3~OD): δ 153.93, 141.90, 141.03, 136.14, 130.99, 130.86, 130.66, 130.30, 129.86, 129.80, 128.50, 128.44, 128.37, 124.76, 123.80, 123.66, 123.60, 122.61, 54.27, 51.49, 36.09. LC-TOF (M + H^+^) calcd for C~25~H~26~N~5~S~2~ 460.1624, found 460.1620.

*N*-(4-(2-(Ethyl(3-(thiophene-2-carboximidamido)benzyl)amino)ethyl)phenyl)thiophene-2-carboximidamide (**15**) {#sec5.5.9}
--------------------------------------------------------------------------------------------------------------

**35** was synthesized by general procedure B using 3-nitrobenzaldehyde and 2-(4-nitrophenyl)ethanamine as the starting materials. To a solution of **35** (1 mmol) and acetaldehyde (2 equiv) in THF (10 mL) was added NaBH~4~ (1.2 mmol) in three portions. The reaction mixture was stirred at room temperature for 8 h under a N~2~ atmosphere. The reaction mixture was then quenched with H~2~O (20 mL), extracted with CH~2~Cl~2~, and washed with water and brine. The organic layer was dried over Na~2~SO~4~ and concentrated in vacuo. The residue was purified by column chromatography to yield **39** (yield 64%). **15** was synthesized by general procedures A and D using **39** as the starting material. ^1^H NMR (500 MHz, CD~3~OD): δ 7.69--7.60 (m, 2H), 7.60--7.54 (m, 2H), 7.36 (t, *J* = 7.5 Hz, 1H), 7.24--7.17 (m, 2H), 7.14--7.09 (m, 3H), 7.05--6.99 (m, 1H), 6.96--6.87 (m, 3H), 3.72 (s, 2H), 2.88--2.73 (m, 4H), 2.72--2.64 (q, *J* = 7.0 Hz, 2H), 1.16 (t, *J* = 7.0 Hz, 3H). ^13^C NMR (125 MHz, CD~3~OD): δ 150.04, 141.15, 141.01, 136.83, 130.90, 130.43, 129.86, 129.79, 128.43, 128.37, 128.35, 125.79, 124.76, 123.65, 122.58, 58.73, 55.97, 33.01, 11.75. LC-TOF (M + H^+^) calcd for C~27~H~30~N~5~S~2~ 488.1937, found 488.1932.

*N*-(3-(((3-Fluorophenethyl)amino)methyl)phenyl)thiophene-2-carboximidamide (**16**) {#sec5.5.10}
------------------------------------------------------------------------------------

**16** was synthesized by the same procedures as those to prepare **13** using 3-fluorobenzaldehyde as the starting material. ^1^H NMR (400 MHz, CD~3~OD): δ 8.18--8.04 (m, 2H), 7.81--7.69 (m, 2H), 7.65 (t, *J* = 7.5 Hz, 1H), 7.58--7.50 (m, 1H), 7.41--7.28 (m, 2H), 7.18--7.06 (m, 2H), 7.03--6.93 (m, 1H), 4.37 (s, 2H), 3.42--3.31 (m, 2H), 3.20--3.10 (m, 2H). ^13^C NMR (100 MHz, CD~3~OD): δ 164.17, 161.74 (s), 139.31 (d, *J* = 7.5 Hz), 134.72, 134.45, 134.22, 133.50, 130.87, 130.55, 130.34 (d, *J* = 7.5 Hz), 128.66, 127.22, 126.47, 124.49, 124.46, 115.30 (d, *J* = 20 Hz), 113.56 (d, *J* = 20 Hz), 109.99, 50.38, 48.27, 31.49 (d, *J* = 2.0 Hz). LC-TOF (M + H^+^) calcd for C~20~H~21~FN~3~S 354.1435, found 354.1441.

*N*-(3-((Ethyl(3-fluorophenethyl)amino)methyl)phenyl)thiophene-2-carboximidamide (**17**) {#sec5.5.11}
-----------------------------------------------------------------------------------------

**17** was synthesized by the same procedures as those to prepare **15** using 3-fluorobenzaldehyde and 2-(3-nitrophenyl)ethanamine as the starting materials. ^1^H NMR (400 MHz, CD~3~OD): δ 7.85--7.72 (m, 2H), 7.43 (t, *J* = 7.5 Hz, 1H), 7.31--7.17 (m, 4H), 7.12 (dt, *J* = 7.5, 1.0 Hz, 1H), 7.02 (dt, *J* = 7.5, 1.0 Hz, 1H), 6.97 (dt, *J* = 9.0, 2.5 Hz, 1H), 6.88 (td, *J* = 9.0, 2.5 Hz, 1H), 3.96 (s, 2H), 2.99--2.82 (m, 6H), 1.18 (t, *J* = 7.0 Hz, 3H). ^13^C NMR (100 MHz, CD~3~OD): δ 164.05, 161.62, 141.73 (d, *J* = 7.5 Hz), 135.05, 130.92, 130.00, 129.91, 129.82, 129.80, 127.70, 126.86, 124.80, 124.44, 124.41, 123.27, 115.19 (d, *J* = 20 Hz), 112.72 (d, *J* = 20 Hz), 109.99, 56.82, 53.51, 47.10, 31.10, 9.67. LC-TOF (M + H^+^) calcd for C~22~H~25~FN~3~S 382.1748, found 382.1742.

Enzyme Assays {#sec5.6}
-------------

The three isozymes, rat nNOS, murine macrophage iNOS, and bovine eNOS, were recombinant enzymes, overexpressed (in *Escherichia coli*) and isolated as reported.^[@ref28]−[@ref30]^*K*~i~ values for inhibitors **7**--**17** were measured for the three different isoforms of NOS using [l]{.smallcaps}-arginine as a substrate. The formation of nitric oxide was measured using the hemoglobin capture assay described previously.^[@ref31]^ All NOS isozymes were assayed using the Synergy H1 hybrid multimode microplate reader (BioTek Instruments, Inc.) at 37 °C in a 100 mM Hepes buffer (pH 7.4) containing 10 μM [l]{.smallcaps}-arginine, 0.83 mM CaCl~2~, 320 units/mL calmodulin, 100 μM NADPH, 10 μM H~4~B, and 3.0 μM oxyhemoglobin (for iNOS assays, no Ca^2+^ and calmodulin was added). The assay was initiated by the addition of enzyme, and the initial rates of the enzymatic reactions were determined by monitoring the formation of NO--hemoglobin complex at 401 nm for 60 s. The apparent *K*~i~ values were obtained by measuring the percent enzyme inhibition in the presence of 10 μM [l]{.smallcaps}-arginine with at least five concentrations of inhibitor. The parameters of the following inhibition equation were fitted to the initial velocity data: % inhibition = 100\[I\]/{\[I\] + *K*~i~(1 + \[S\]/*K*~m~)}. *K*~m~ values for [l]{.smallcaps}-arginine were 1.3 μM (nNOS), 8.2 μM (iNOS), and 1.7 μM (eNOS). The selectivity of an inhibitor was defined as the ratio of the respective *K*~i~ values.

Inhibitor Complex Crystal Preparation {#sec5.7}
-------------------------------------

The nNOS or eNOS heme domain proteins used for crystallographic studies were produced by limited trypsin digest from the corresponding full length enzymes and further purified through a Superdex 200 gel filtration column (GE Healthcare) as described previously.^[@ref32],[@ref33]^ The nNOS heme domain at 7--9 mg/mL containing 20 mM histidine or the eNOS heme domain at 12 mg/mL containing 2 mM imidazole were used for the sitting drop vapor diffusion crystallization setup under the conditions reported before.^[@ref32],[@ref33]^ Fresh crystals (1--2 day old) were first passed stepwise through cryoprotectant solutions as described^[@ref32],[@ref33]^ and then soaked with 10 mM inhibitor for 4--6 h at 4 °C before being mounted on nylon loops and flash cooled by plunging into liquid nitrogen.

X-ray Diffraction Data Collection, Processing, and Structure Refinement {#sec5.8}
-----------------------------------------------------------------------

The cryogenic (100 K) X-ray diffraction data were collected remotely at various beamlines at Stanford Synchrotron Radiation Lightsource through the data collection control software Blu-Ice^[@ref34]^ and a crystal mounting robot. Raw data frames were indexed, integrated, and scaled using HKL2000.^[@ref35]^ The binding of inhibitors was detected by the initial difference Fourier maps calculated with REFMAC.^[@ref36]^ The inhibitor molecules were then modeled in COOT^[@ref37]^ and refined using REFMAC. Disordering in portions of inhibitor bound in the NOS active site was often observed, resulting in poor density quality. However, partial structural features usually could still be visible if the contour level of the sigmaA weighted 2*m*\|*F*~o~\| -- *D*\|*F*~c~\| map dropped to 0.5 σ, which afforded building of a reasonable model into the disordered regions. Water molecules were added in REFMAC and checked by COOT. The TLS^[@ref38]^ protocol was implemented in the final stage of refinements with each subunit as one TLS group. The omit *F*~o~ -- *F*~c~ density maps were calculated by repeating the last round of TLS refinement with inhibitor coordinate removed from the input PDB file to generate the coefficients DELFWT and SIGDELFWT. The refined structures were validated in COOT before deposition in the RCSB Protein Data Bank. The crystallographic data collection and structure refinement statistics are summarized in Table [5](#tbl5){ref-type="other"} with PDB accession codes included.

###### Crystallographic Data Collection and Refinement Statistics

  data set[a](#t4afn1){ref-type="table-fn"}              nNOS-**7**           nNOS-**9**           nNOS-**11**          nNOS-**13**
  ------------------------------------------------------ -------------------- -------------------- -------------------- --------------------
  Data Collection                                                                                                       
  PDB code                                               4KCH                 4KCI                 4KCJ                 4KCK
  space group                                            *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~
  cell dimensions *a*, *b*, *c* (Å)                      51.7, 111.6, 165.0   51.8, 111.9, 165.0   51.8, 110.0, 164.7   51.9, 111.0, 165.3
  resolution (Å)                                         2.15 (2.19--2.15)    2.27 (2.31--2.27)    2.05 (2.09--2.05)    2.10 (2.14--2.10)
  *R*~merge~                                             0.066 (0.559)        0.055 (0.677)        0.055 (0.799)        0.069 (0.720)
  *I*/σ*I*                                               20.0 (1.3)           29.7 (1.9)           25.1 (2.1)           20.7 (1.5)
  no. unique reflns                                      52573                44477                61070                52371
  completeness (%)                                       99.4 (98.1)          98.3 (97.8)          99.6 (97.8)          92.6 (100.0)
  redundancy                                             3.6 (3.6)            4.0 (4.2)            3.6 (3.4)            3.5 (3.7)
  Refinement                                                                                                            
  resolution (Å)                                         2.15                 2.27                 2.05                 2.10
  no. reflns used                                        49887                42147                57366                49419
  *R*~work~/*R*~free~[b](#t4afn2){ref-type="table-fn"}   0.194/0.250          0.181/0.238          0.195/0.242          0.216/0.264
  no. atoms                                                                                                              
  protein                                                6659                 6659                 6665                 6681
  ligand/ion                                             185                  189                  193                  179
  water                                                  167                  122                  259                  379
  RMS deviations                                                                                                         
  bond lengths (Å)                                       0.011                0.016                0.013                0.012
  bond angles (deg)                                      2.02                 2.27                 2.11                 2.10

  data set[a](#t4afn1){ref-type="table-fn"}              nNOS-**14**          nNOS-**15**          nNOS-**16**          nNOS-**17**
  ------------------------------------------------------ -------------------- -------------------- -------------------- --------------------
  Data Collection                                                                                                       
  PDB code                                               4KCL                 4KCM                 4KCN                 4KCO
  space group                                            *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~
  cell dimensions *a*, *b*, *c* (Å)                      52.1, 111.1, 165.1   51.7, 110.8, 165.2   52.1, 111.0, 165.0   52.0, 110.9, 165.0
  resolution (Å)                                         1.93 (1.96--1.93)    2.08 (2.12--2.08)    1.85 (1.88--1.85)    1.86 (1.89--1.86)
  *R*~merge~                                             0.057 (0.479)        0.068 (0.762)        0.050 (0.660)        0.057 (0.680)
  *I*/σ*I*                                               26.3 (2.1)           23.1 (1.7)           29.2 (2.6)           28.2 (2.1)
  no. unique reflns                                      71898                58123                82346                81114
  completeness (%)                                       98.0 (97.8)          99.6 (100.0)         99.3 (99.9)          99.4 (100.0)
  redundancy                                             3.3 (3.2)            3.8 (3.8)            4.0 (4.1)            3.9 (3.8)
  Refinement                                                                                                            
  resolution (Å)                                         2.10                 2.07                 1.85                 1.86
  no. reflns used                                        68,060               55,146               77,959               76,678
  *R*~work~/*R*~free~[b](#t4afn2){ref-type="table-fn"}   0.182/0.213          0.191/0.236          0.185/0.217          0.187/0.220
  no. atoms                                                                                                              
  protein                                                6666                 6668                 6677                 6685
  ligand/ion                                             195                  188                  219                  177
  water                                                  341                  224                  397                  380
  RMS deviations                                                                                                         
  bond lengths (Å)                                       0.011                0.011                0.012                0.014
  bond angles (deg)                                      1.45                 2.05                 1.52                 1.62

  data set[a](#t4afn1){ref-type="table-fn"}              eNOS-**14**          eNOS-**15**          eNOS-**16**          eNOS-**17**
  ------------------------------------------------------ -------------------- -------------------- -------------------- --------------------
  Data Collection                                                                                                       
  PDB code                                               4KCP                 4KCQ                 4KCR                 4KCS
  space group                                            *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~      *P*2~1~2~1~2~1~
  cell dimensions *a*, *b*, *c* (Å)                      57.7, 106.2, 156.8   57.7, 106.4, 156.7   57.6, 106.2, 156.5   57.7, 106.4, 157.1
  resolution (Å)                                         2.07 (2.11--2.07)    2.03 (2.07--2.03)    2.09 (2.13--2.09)    2.05 (2.09--2.05)
  *R*~merge~                                             0.060 (0.712)        0.064 (0.494)        0.059 (0.576)        0.051 (0.528)
  *I*/σ*I*                                               24.2 (1.9)           26.9 (2.6)           27.3 (2.6)           31.0 (2.9)
  no. unique reflns                                      59332                62254                57743                61246
  Completeness (%)                                       99.1 (99.9)          98.4 (99.7)          99.7 (100.0)         99.2 (100.0)
  Redundancy                                             4.0 (4.0)            3.9 (3.9)            4.0 (4.1)            4.0 (4.0)
  Refinement                                                                                                            
  Resolution (Å)                                         2.07                 2.03                 2.09                 2.05
  No. reflns used                                        56198                59095                54719                58050
  *R*~work~/*R*~free~[b](#t4afn2){ref-type="table-fn"}   0.166/0.213          0.179/0.224          0.164/0.205          0.168/0.213
  No. atoms                                                                                                              
  protein                                                6446                 6429                 6436                 6446
  ligand/ion                                             216                  223                  206                  201
  water                                                  305                  359                  354                  350
  RMS deviations                                                                                                         
  bond lengths (Å)                                       0.020                0.013                0.011                0.020
  bond angles (deg)                                      2.02                 1.63                 1.45                 2.05

See Figure [3](#fig3){ref-type="fig"} for the inhibitor chemical structure.

*R*~free~ was calculated with the 5% of reflections set aside throughout the refinement. The set of reflections for the *R*~free~ calculation were kept the same for all data sets of each isoform according to those used in the data of the starting model.

Details of HPLC purity and copies of complete spectroscopic data of compounds **7**--**17**. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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NOS

:   nitric oxide synthase

NO

:   nitric oxide

NADPH

:   reduced nicotinamide adenine dinucleotide phosphate

NHA

:   *N*^ω^-hydroxy-[l]{.smallcaps}-arginine

nNOS

:   neuronal nitric oxide synthase

eNOS

:   endothelial nitric oxide synthase

iNOS

:   inducible nitric oxide synthase

H-bond

:   hydrogen bond
